TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase III Comparing Sequential Therapy With TPF/Chemoradiation (ST) To Cisplatinum-Based Chemoradiotherapy [PARADIGM TRIAL]
Brief Summary: RATIONALE: Drugs used in chemotherapy, such as docetaxel, cisplatin, fluorouracil, and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. It is not yet known which regimen of chemotherapy and radiation therapy is most effective in treating head and neck cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of chemotherapy and radiation therapy in treating patients who have stage III or stage IV head and neck cancer.


Options:
A: Intervention Type: DRUG; Name: cetuximab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Radiotherapy 70 Gy, 35 fractions; Assigned to Arm(s): N/A
B: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: carboplatin, Drug: cisplatin, Drug: docetaxel, Drug: fluorouracil | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Drug: cisplatin | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): Arm I | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): Arm I | Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): Arm I
C: Arm Label: Standard fractionation RT + cisplatin; Type: OTHER; Interventions: Drug: cisplatin, Radiation: Standard fractionation RT, Procedure: Conventional surgery for select patients | Arm Label: Accelerated fractionation RT + cisplatin; Type: EXPERIMENTAL; Interventions: Drug: cisplatin, Radiation: Accelerated fractionation radiation therapy, Procedure: Conventional surgery for select patients | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Accelerated fractionation RT + cisplatin, Standard fractionation RT + cisplatin | Intervention Type: RADIATION; Name: Standard fractionation RT; Assigned to Arm(s): Standard fractionation RT + cisplatin | Intervention Type: RADIATION; Name: Accelerated fractionation radiation therapy; Assigned to Arm(s): Accelerated fractionation RT + cisplatin | Intervention Type: PROCEDURE; Name: Conventional surgery for select patients; Assigned to Arm(s): Accelerated fractionation RT + cisplatin, Standard fractionation RT + cisplatin
D: Arm Label: Cetuximab Plus Chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU) | Arm Label: Chemotherapy alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Platinum (Cisplatin or Carboplatin) + 5-FU | Intervention Type: DRUG; Name: Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU); Assigned to Arm(s): Cetuximab Plus Chemotherapy | Intervention Type: DRUG; Name: Platinum (Cisplatin or Carboplatin) + 5-FU; Assigned to Arm(s): Chemotherapy alone

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase III Comparing Sequential Therapy With TPF/Chemoradiation (ST) To Cisplatinum-Based Chemoradiotherapy [PARADIGM TRIAL]
Brief Summary: RATIONALE: Drugs used in chemotherapy, such as docetaxel, cisplatin, fluorouracil, and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. It is not yet known which regimen of chemotherapy and radiation therapy is most effective in treating head and neck cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of chemotherapy and radiation therapy in treating patients who have stage III or stage IV head and neck cancer.


Options:
A: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: carboplatin, Drug: cisplatin, Drug: docetaxel, Drug: fluorouracil | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Drug: cisplatin | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): Arm I | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): Arm I | Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): Arm I
B: Arm Label: Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Everolimus | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: RT+CDDP/5-FU; Type: ACTIVE_COMPARATOR; Interventions: Drug: RT+CDDP/5-FU | Arm Label: RT+CETUXIMAB; Type: EXPERIMENTAL; Interventions: Drug: RT+CETUXIMAB | Arm Label: INDUCTION CTx(TPF)+(RT+CDDP/5-FU); Type: ACTIVE_COMPARATOR; Interventions: Drug: INDUCTION CTx(TPF)+(RT+CDDP/5-FU) | Arm Label: INDUCTION CTx(TPF)+(RT+CETUXIMAB); Type: EXPERIMENTAL; Interventions: Drug: INDUCTION CTx(TPF)+(RT+CETUXIMAB) | Intervention Type: DRUG; Name: RT+CDDP/5-FU; Assigned to Arm(s): RT+CDDP/5-FU | Intervention Type: DRUG; Name: RT+CETUXIMAB; Assigned to Arm(s): RT+CETUXIMAB | Intervention Type: DRUG; Name: INDUCTION CTx(TPF)+(RT+CDDP/5-FU); Assigned to Arm(s): INDUCTION CTx(TPF)+(RT+CDDP/5-FU) | Intervention Type: DRUG; Name: INDUCTION CTx(TPF)+(RT+CETUXIMAB); Assigned to Arm(s): INDUCTION CTx(TPF)+(RT+CETUXIMAB)
D: Arm Label: Taxotere, Cisplatin, 5-Fluorouracil (5-FU); Type: EXPERIMENTAL; Interventions: Drug: Taxotere, Cisplatin, 5-Fluorouracil (5-FU) | Intervention Type: DRUG; Name: Taxotere, Cisplatin, 5-Fluorouracil (5-FU); Assigned to Arm(s): Taxotere, Cisplatin, 5-Fluorouracil (5-FU)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Trial Of BAY 43-9006, A Novel Raf Kinase Inhibitor Plus Paclitaxel/Carboplatin In Women With Recurrent Platinum Sensitive Epithelial Ovarian, Peritoneal Or Fallopian Tube Cancer
Brief Summary: Sorafenib may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving sorafenib together with chemotherapy may kill more tumor cells. This randomized phase II trial is studying how well giving sorafenib together with paclitaxel and carboplatin works in treating patients with recurrent ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. (Sorafenib only group closed as of 10/10/2008).


Options:
A: Arm Label: Arm I (closed to accrual 10/10/2008); Type: EXPERIMENTAL; Interventions: Drug: Sorafenib Tosylate | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Sorafenib Tosylate | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm II | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm II | Intervention Type: DRUG; Name: Sorafenib Tosylate; Assigned to Arm(s): Arm I (closed to accrual 10/10/2008), Arm II
B: Intervention Type: BIOLOGICAL; Name: bevacizumab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: questionnaire administration; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: study of socioeconomic and demographic variables; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A
C: Arm Label: Olaparib and Cediranib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib, Drug: Cediranib | Arm Label: Olaparib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olaparib | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib, Olaparib and Cediranib | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): Olaparib and Cediranib
D: Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: liposomal doxorubicin, Drug: paclitaxel, Drug: topotecan | Arm Label: Chemotherapy + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: liposomal doxorubicin, Drug: paclitaxel, Drug: topotecan | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: liposomal doxorubicin; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: topotecan; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: LACE - Laparoscopic Approach to Cancer of the Endometrium: An International Multicenter Randomized Phase 3 Clinical Trial
Brief Summary: The primary objective of this study is to assess disease-free survival at 4.5 years postoperatively for women with apparent Stage 1 endometrial cancer, comparing patients who are randomised to receive Total Laparoscopic Hysterectomy (TLH) and patients who are randomised to receive Total Abdominal Hysterectomy (TAH).


Options:
A: Arm Label: Standard Perioperative (SP) care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: ERAS protocol; Type: EXPERIMENTAL; Interventions: Other: Changes in preoperative care, Other: Changes in intraoperative care, Other: Changes in postoperative care | Intervention Type: OTHER; Name: Changes in preoperative care; Assigned to Arm(s): ERAS protocol | Intervention Type: OTHER; Name: Changes in intraoperative care; Assigned to Arm(s): ERAS protocol | Intervention Type: OTHER; Name: Changes in postoperative care; Assigned to Arm(s): ERAS protocol
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Total Abdominal Hysterectomy | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Total Laparoscopic Hysterectomy | Intervention Type: PROCEDURE; Name: Total Abdominal Hysterectomy; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Total Laparoscopic Hysterectomy; Assigned to Arm(s): 2
C: Arm Label: fast track recovery; Type: EXPERIMENTAL; Interventions: Procedure: fast track recovery surgery with whey protein infused carbohydrate loading and early oral feeding | Arm Label: conventional; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: fast track recovery surgery with whey protein infused carbohydrate loading and early oral feeding; Assigned to Arm(s): fast track recovery
D: Arm Label: Control Group (Standard Laparotomy); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Laparotomy, Drug: intravenous narcotics, Drug: standard anesthesia | Arm Label: Rapid Recovery Group; Type: EXPERIMENTAL; Interventions: Procedure: Laparotomy, Drug: regional anesthesia, Drug: Non-steroidal anti-inflammatory drugs | Intervention Type: PROCEDURE; Name: Laparotomy; Assigned to Arm(s): Control Group (Standard Laparotomy), Rapid Recovery Group | Intervention Type: DRUG; Name: intravenous narcotics; Assigned to Arm(s): Control Group (Standard Laparotomy) | Intervention Type: DRUG; Name: standard anesthesia; Assigned to Arm(s): Control Group (Standard Laparotomy) | Intervention Type: DRUG; Name: regional anesthesia; Assigned to Arm(s): Rapid Recovery Group | Intervention Type: DRUG; Name: Non-steroidal anti-inflammatory drugs; Assigned to Arm(s): Rapid Recovery Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Single Dose, Randomized, Double-blind Crossover Comparison of Combivent CFC MDI and Albuterol HFA MDI in Patients With Moderate to Severe Persistent Asthma and Persistent Symptoms Despite Treatment With Inhaled Corticosteroids
Brief Summary: The purpose of this study is to demonstrate the superior bronchodilator efficacy of inhaled Combivent® CFC MDI vs. Albuterol HFA MDI in moderate to severe asthma patients.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: montelukast sodium | Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): 1
B: Intervention Type: DRUG; Name: Combivent® CFC MDI; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Albuterol HFA MDI; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Montelukast; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: placebo (unspecified) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: montelukast sodium | Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Comparator: placebo (unspecified); Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients With Active Ulcerative Colitis
Brief Summary: The purpose of this study is to evaluate the effectiveness and safety of infliximab (Remicade) in patients with Ulcerative Colitis. Infliximab (Remicade) targets specific proteins in the body's immune system to help control the development of inflammation to help reduce painful disease.


Options:
A: Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): N/A
B: Arm Label: Golimumab (CNTO 148) with Methotrexate (MTX); Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Drug: MTX | Arm Label: Infliximab with MTX; Type: EXPERIMENTAL; Interventions: Drug: MTX, Drug: Infliximab | Arm Label: Placebo with MTX; Type: PLACEBO_COMPARATOR; Interventions: Drug: MTX, Drug: Placebo | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): Golimumab (CNTO 148) with Methotrexate (MTX) | Intervention Type: DRUG; Name: MTX; Assigned to Arm(s): Golimumab (CNTO 148) with Methotrexate (MTX), Infliximab with MTX, Placebo with MTX | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo with MTX | Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): Infliximab with MTX
C: Intervention Type: DRUG; Name: Certolizumab Pegol (CDP870); Assigned to Arm(s): N/A
D: Arm Label: Certolizumab Pegol; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab Pegol | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol; Assigned to Arm(s): Certolizumab Pegol

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients With Active Ulcerative Colitis
Brief Summary: The purpose of this study is to evaluate the effectiveness and safety of infliximab (Remicade) in patients with Ulcerative Colitis. Infliximab (Remicade) targets specific proteins in the body's immune system to help control the development of inflammation to help reduce painful disease.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: budesonide | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: mesalazine | Intervention Type: DRUG; Name: budesonide; Assigned to Arm(s): A | Intervention Type: DRUG; Name: mesalazine; Assigned to Arm(s): B
B: Arm Label: 1: budesonide-MMX® 6 mg; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling, endoscopy, Drug: Budesonide MMX® 6 mg | Arm Label: 2: budesonide-MMX® 9 mg; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling, endoscopy, Drug: Budesonide MMX® 9 mg | Arm Label: 3: Entocort EC® 3 mg; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Blood sampling, endoscopy, Drug: Entocort EC® 3 mg | Arm Label: 4: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Blood sampling, endoscopy, Drug: Placebo | Intervention Type: PROCEDURE; Name: Blood sampling, endoscopy; Assigned to Arm(s): 1: budesonide-MMX® 6 mg, 2: budesonide-MMX® 9 mg, 3: Entocort EC® 3 mg, 4: Placebo | Intervention Type: DRUG; Name: Budesonide MMX® 6 mg; Assigned to Arm(s): 1: budesonide-MMX® 6 mg | Intervention Type: DRUG; Name: Budesonide MMX® 9 mg; Assigned to Arm(s): 2: budesonide-MMX® 9 mg | Intervention Type: DRUG; Name: Entocort EC® 3 mg; Assigned to Arm(s): 3: Entocort EC® 3 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4: Placebo
C: Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients With Active Ulcerative Colitis
Brief Summary: The purpose of this study is to evaluate the effectiveness and safety of infliximab (Remicade) in patients with Ulcerative Colitis. Infliximab (Remicade) targets specific proteins in the body's immune system to help control the development of inflammation to help reduce painful disease.


Options:
A: Arm Label: 1 (i); Type: ACTIVE_COMPARATOR; Interventions: Drug: Rituximab | Arm Label: 2 (ii); Type: PLACEBO_COMPARATOR; Interventions: Drug: Rituximab | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): 1 (i), 2 (ii)
B: Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Golimumab 100 mg -> 50 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg, Biological: Golimumab 50 mg | Arm Label: Golimumab 200 mg -> 100 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg, Biological: Golimumab 200 mg | Arm Label: Golimumab 400 mg -> 200 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 200 mg, Biological: Golimumab 400 mg | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Golimumab 100 mg; Assigned to Arm(s): Golimumab 100 mg -> 50 mg, Golimumab 200 mg -> 100 mg | Intervention Type: BIOLOGICAL; Name: Golimumab 200 mg; Assigned to Arm(s): Golimumab 200 mg -> 100 mg, Golimumab 400 mg -> 200 mg | Intervention Type: BIOLOGICAL; Name: Golimumab 400 mg; Assigned to Arm(s): Golimumab 400 mg -> 200 mg | Intervention Type: BIOLOGICAL; Name: Golimumab 50 mg; Assigned to Arm(s): Golimumab 100 mg -> 50 mg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Placebo-Controlled Study of Ethyl Eicosapentanoic Acid (Ethyl-EPA) in Major Depressive Disorder
Brief Summary: The purpose of this study is to examine the effectiveness of ethyl-eicosapentanoic acid (ethyl-EPA), an omega-3 fatty acid, in treating depression.


Options:
A: Intervention Type: DRUG; Name: Ethyl-eicosapentanoic acid (ethyl-EPA); Assigned to Arm(s): N/A
B: Arm Label: Corn Oil; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Corn oil | Arm Label: Omega-3 Fatty Acids; Type: EXPERIMENTAL; Interventions: Drug: Omega 3 Fatty Acids | Intervention Type: DRUG; Name: Omega 3 Fatty Acids; Assigned to Arm(s): Omega-3 Fatty Acids | Intervention Type: DIETARY_SUPPLEMENT; Name: Corn oil; Assigned to Arm(s): Corn Oil
C: Arm Label: Sertraline/omega-3 supplement; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline/omega-3 | Arm Label: Sertraline/corn oil; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sertraline/Corn Oil | Intervention Type: DRUG; Name: Sertraline/omega-3; Assigned to Arm(s): Sertraline/omega-3 supplement | Intervention Type: DRUG; Name: Sertraline/Corn Oil; Assigned to Arm(s): Sertraline/corn oil
D: Arm Label: EPA 3.5 g/day; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Omega-3 fatty acids | Arm Label: Placebo capsules; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Omega-3 fatty acids | Arm Label: DHA 1.75 g/day; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Omega-3 fatty acids | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega-3 fatty acids; Assigned to Arm(s): DHA 1.75 g/day, EPA 3.5 g/day, Placebo capsules

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Delirium in the ICU: a Prospective, Randomized, Trial of Placebo vs. Haloperidol vs. Ziprasidone
Brief Summary: Delirium is associated with increased risk of death, prolonged stay, higher cost of care, and likely long-term brain deficits in survivors. This form of brain dysfunction occurs in intensive care unit (ICU) patients in epidemic proportions, and the scope of this problem is likely to worsen in upcoming years due to the aging of our population and increased utilization of the ICU. Currently, delirium goes unrecognized and untreated in the vast majority of circumstances in the ICU unless the patient presents with hyperactive delirium and agitation. In the latter circumstance, a commonly used typical antipsychotic called haloperidol is considered the principal agent for treating delirium based largely on anecdotal evidence to support its usefulness, though no placebo controlled trials exist. There are no FDA approved medications for delirium. The atypical antipsychotics provide a promising alternative for the treatment of delirium due to their enhanced beneficial effects on positive (agitated) and negative (quiet) symptoms proven in mania and schizophrenia, reduced risk for side effects common to haloperidol such as extrapyramidal symptomatology, and less potentially lethal heart rhythm disturbances. It is imperative that well-designed phase II studies to determine proof of principle be conducted. A pilot study of feasibility to begin assessing the role of antipsychotics in the management of ICU delirium.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Rivastigmine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivastigmine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: A - placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ziprasidone | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Haloperidol | Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Haloperidol; Assigned to Arm(s): C | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): A - placebo
C: Arm Label: Dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine | Arm Label: Propofol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Propofol | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Propofol; Assigned to Arm(s): Propofol
D: Arm Label: Dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine HCL Injection | Arm Label: Midazolam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam Injection | Intervention Type: DRUG; Name: Dexmedetomidine HCL Injection; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Midazolam Injection; Assigned to Arm(s): Midazolam

Answer: B